Viviane Marie Conraads
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Viviane Marie Conraads has a total of 310 co-authors. Here are the top co-authors by number of shared publications:
Christiaan J. Vrints
Laboratory of Cellular and Molecular Cardiology, Department of Cardiology, University Hospital Antwerp, Wilrijkstraat 10, 2650 Antwerp, Belgium; Cardiovascular Diseases, Department of Translational Pathophysiological Research, University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium
38 shared publications- Paul Beckers
Department of Cardiology, Antwerp University Hospital, Edegem, Belgium
23 shared publications Vicky Y. Hoymans
16 shared publicationsChristiaan J Vrints
Department of Cardiology, Antwerp University Hospital, Edegem, Belgium
10 shared publicationsEmeline M. Van Craenenbroeck
10 shared publicationsChristiaan Vrints
Department of Cardiology, University Hospital of Antwerp, Edegem
8 shared publications
Latest Publications
- 1 July 2014
- Published by Elsevier in International Journal of Cardiology
- Vol. 174 (3) , 881-883
Circulating Angiogenic Cells from obese children do not display leptin resistance
- 1 July 2014
- Published by Elsevier in International Journal of Cardiology
- Vol. 174 (3) , 881-883
Circulating Angiogenic Cells from obese children do not display leptin resistance
- 1 October 2013
- Published by Elsevier in International Journal of Cardiology
- Vol. 168 (4) , 3532-3536
Rationale and design of a randomized trial on the effectiveness of aerobic interval training in patients with coronary artery disease: The SAINTEX-CAD study
- 1 October 2013
- Published by Elsevier in International Journal of Cardiology
- Vol. 168 (4) , 3532-3536
Rationale and design of a randomized trial on the effectiveness of aerobic interval training in patients with coronary artery disease: The SAINTEX-CAD study
- 1 September 2013
- Published by Elsevier in International Journal of Cardiology
- Vol. 167 (5) , 1688-1695
Quantification of circulating CD34+/KDR+/CD45dim endothelial progenitor cells: Analytical considerations
- 1 September 2013
- Published by Elsevier in International Journal of Cardiology
- Vol. 167 (5) , 1688-1695
Quantification of circulating CD34+/KDR+/CD45dim endothelial progenitor cells: Analytical considerations
- 1 June 2013
- Published by Elsevier in International Journal of Cardiology
- Vol. 166 (2) , 310-314
Mending injured endothelium in chronic heart failure: A new target for exercise training
- 1 June 2013
- Published by Elsevier in International Journal of Cardiology
- Vol. 166 (2) , 310-314
Mending injured endothelium in chronic heart failure: A new target for exercise training
- Open Access
- 1 January 2013
- Published by Springer Nature in Trials
- Vol. 14 (1) , 104
Effect of comprehensive cardiac rehabilitation after heart valve surgery (CopenHeartVR): study protocol for a randomised clinical trial
Heart valve diseases are common with an estimated prevalence of 2.5% in the Western world. The number is rising due to an ageing population. Once symptomatic, heart valve diseases are potentially lethal, and heavily influence daily living and quality of life. Surgical treatment, either valve replacement or repair, remains the treatment of choice. However, post surgery, the transition to daily living may become a physical, mental and social challenge. We hypothesise that a comprehensive cardiac rehabilitation programme can improve physical capacity and self-assessed mental health and reduce hospitalisation and healthcare costs after heart valve surgery. A randomised clinical trial, CopenHeartVR, aims to investigate whether cardiac rehabilitation in addition to usual care is superior to treatment as usual after heart valve surgery. The trial will randomly allocate 210 patients, 1:1 intervention to control group, using central randomisation, and blinded outcome assessment and statistical analyses. The intervention consists of 12 weeks of physical exercise, and a psycho-educational intervention comprising five consultations. Primary outcome is peak oxygen uptake (VO2 peak) measured by cardiopulmonary exercise testing with ventilatory gas analysis. Secondary outcome is self-assessed mental health measured by the standardised questionnaire Short Form 36. Also, long-term healthcare utilisation and mortality as well as biochemistry, echocardiography and cost-benefit will be assessed. A mixed-method design is used to evaluate qualitative and quantitative findings encompassing a survey-based study before the trial and a qualitative pre- and post-intervention study. The study is approved by the local regional Research Ethics Committee (H-1-2011-157), and the Danish Data Protection Agency (j.nr. 2007-58-0015). ClinicalTrials.gov ( http://NCT01558765 ).
- 1 January 2013
- Published by Springer Nature in Trials
- Vol. 14 (1) , 104
Open AccessEffect of comprehensive cardiac rehabilitation after heart valve surgery (CopenHeartVR): study protocol for a randomised clinical trial
Heart valve diseases are common with an estimated prevalence of 2.5% in the Western world. The number is rising due to an ageing population. Once symptomatic, heart valve diseases are potentially lethal, and heavily influence daily living and quality of life. Surgical treatment, either valve replacement or repair, remains the treatment of choice. However, post surgery, the transition to daily living may become a physical, mental and social challenge. We hypothesise that a comprehensive cardiac rehabilitation programme can improve physical capacity and self-assessed mental health and reduce hospitalisation and healthcare costs after heart valve surgery. A randomised clinical trial, CopenHeartVR, aims to investigate whether cardiac rehabilitation in addition to usual care is superior to treatment as usual after heart valve surgery. The trial will randomly allocate 210 patients, 1:1 intervention to control group, using central randomisation, and blinded outcome assessment and statistical analyses. The intervention consists of 12 weeks of physical exercise, and a psycho-educational intervention comprising five consultations. Primary outcome is peak oxygen uptake (VO2 peak) measured by cardiopulmonary exercise testing with ventilatory gas analysis. Secondary outcome is self-assessed mental health measured by the standardised questionnaire Short Form 36. Also, long-term healthcare utilisation and mortality as well as biochemistry, echocardiography and cost-benefit will be assessed. A mixed-method design is used to evaluate qualitative and quantitative findings encompassing a survey-based study before the trial and a qualitative pre- and post-intervention study. The study is approved by the local regional Research Ethics Committee (H-1-2011-157), and the Danish Data Protection Agency (j.nr. 2007-58-0015). ClinicalTrials.gov ( http://NCT01558765 ).
- 1 November 2012
- Published by Elsevier in Microvascular Research
- Vol. 84 (3) , 384-386
TransFix® for delayed flow cytometry of endothelial progenitor cells and angiogenic T cells
- 1 November 2012
- Published by Elsevier in Microvascular Research
- Vol. 84 (3) , 384-386
TransFix® for delayed flow cytometry of endothelial progenitor cells and angiogenic T cells
- Top Cited Papers
- 30 October 2012
- Published by Wolters Kluwer Health in Circulation
- Vol. 126 (18) , 2261-2274
Clinical Recommendations for Cardiopulmonary Exercise Testing Data Assessment in Specific Patient Populations
- 30 October 2012
- Published by Wolters Kluwer Health in Circulation
- Vol. 126 (18) , 2261-2274
Top Cited PapersClinical Recommendations for Cardiopulmonary Exercise Testing Data Assessment in Specific Patient Populations
- 23 October 2012
- Published by Springer Nature in Heart Failure Reviews
- Vol. 18 (5) , 557-566
Adiponectin: key role and potential target to reverse energy wasting in chronic heart failure
The concept of skeletal muscle myopathy as a main determinant of exercise intolerance in chronic heart failure (HF) is gaining acceptance. Symptoms that typify HF patients, including shortness of breath and fatigue, are often directly related to the abnormalities of the skeletal muscle in HF. Besides muscular wasting, alterations in skeletal muscle energy metabolism, including insulin resistance, have been implicated in HF. Adiponectin, an adipocytokine with insulin-sensitizing properties, receives increasing interest in HF. Circulating adiponectin levels are elevated in HF patients, but high levels are paradoxically associated with poor outcome. Previous analysis of m. vastus lateralis biopsies in HF patients highlighted a striking functional adiponectin resistance. Together with increased circulating adiponectin levels, adiponectin expression within the skeletal muscle is elevated in HF patients, whereas the expression of the main adiponectin receptor and genes involved in the downstream pathway of lipid and glucose metabolism is downregulated. In addition, the adiponectin-related metabolic disturbances strongly correlate with aerobic capacity (VO2 peak), sub-maximal exercise performance and muscle strength. These observations strengthen our hypothesis that adiponectin and its receptors play a key role in the development and progression of the “heart failure myopathy”. The question whether adiponectin exerts beneficial rather than detrimental effects in HF is still left unanswered. This current research overview will elucidate the emerging role of adiponectin in HF and suggests potential therapeutic targets to tackle energy wasting in these patients.
- 23 October 2012
- Published by Springer Nature in Heart Failure Reviews
- Vol. 18 (5) , 557-566
Adiponectin: key role and potential target to reverse energy wasting in chronic heart failure
The concept of skeletal muscle myopathy as a main determinant of exercise intolerance in chronic heart failure (HF) is gaining acceptance. Symptoms that typify HF patients, including shortness of breath and fatigue, are often directly related to the abnormalities of the skeletal muscle in HF. Besides muscular wasting, alterations in skeletal muscle energy metabolism, including insulin resistance, have been implicated in HF. Adiponectin, an adipocytokine with insulin-sensitizing properties, receives increasing interest in HF. Circulating adiponectin levels are elevated in HF patients, but high levels are paradoxically associated with poor outcome. Previous analysis of m. vastus lateralis biopsies in HF patients highlighted a striking functional adiponectin resistance. Together with increased circulating adiponectin levels, adiponectin expression within the skeletal muscle is elevated in HF patients, whereas the expression of the main adiponectin receptor and genes involved in the downstream pathway of lipid and glucose metabolism is downregulated. In addition, the adiponectin-related metabolic disturbances strongly correlate with aerobic capacity (VO2 peak), sub-maximal exercise performance and muscle strength. These observations strengthen our hypothesis that adiponectin and its receptors play a key role in the development and progression of the “heart failure myopathy”. The question whether adiponectin exerts beneficial rather than detrimental effects in HF is still left unanswered. This current research overview will elucidate the emerging role of adiponectin in HF and suggests potential therapeutic targets to tackle energy wasting in these patients.
- 1 August 2012
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 67 (4) , 439-444
A critical review on telemonitoring in heart failure
Morbidity and mortality remain high in heart failure despite considerable progress achieved with medical therapy and electrical devices. A multidisciplinary approach is actually strongly recommended. In order to provide optimal care to the ever-growing population of patients with heart failure, telemonitoring has been proposed as a modality to improve usual care. The aim of this review is to provide an overview of the existing evidence on telemonitoring in HF. Despite two major meta-analyses with favourable results, two recent, large, multicentre, randomized controlled trials, one with a sophisticated technical remote telemonitoring approach (TIM-HF) in stable chronic HF and the other with a comprehensive telephone-based interactive voice-response monitoring (Tele-HF) in patients recently hospitalized for heart failure, have been performed and both failed to demonstrate a clinical benefit for telemonitoring. Newer technologies or other modalities, such as collaboration between a general practitioner and a heart failure clinic facilitated by telemonitoring should be further evaluated. Dedicated telemonitoring for heart failure may be a practical adjunct in selective centres and patients, on top of usual care, including education and a multidisciplinary approach. However, prior to being accepted as a standard of care, more evidence from large, randomized clinical trials is required.
- 1 August 2012
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 67 (4) , 439-444
A critical review on telemonitoring in heart failure
Morbidity and mortality remain high in heart failure despite considerable progress achieved with medical therapy and electrical devices. A multidisciplinary approach is actually strongly recommended. In order to provide optimal care to the ever-growing population of patients with heart failure, telemonitoring has been proposed as a modality to improve usual care. The aim of this review is to provide an overview of the existing evidence on telemonitoring in HF. Despite two major meta-analyses with favourable results, two recent, large, multicentre, randomized controlled trials, one with a sophisticated technical remote telemonitoring approach (TIM-HF) in stable chronic HF and the other with a comprehensive telephone-based interactive voice-response monitoring (Tele-HF) in patients recently hospitalized for heart failure, have been performed and both failed to demonstrate a clinical benefit for telemonitoring. Newer technologies or other modalities, such as collaboration between a general practitioner and a heart failure clinic facilitated by telemonitoring should be further evaluated. Dedicated telemonitoring for heart failure may be a practical adjunct in selective centres and patients, on top of usual care, including education and a multidisciplinary approach. However, prior to being accepted as a standard of care, more evidence from large, randomized clinical trials is required.
- 1 July 2012
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 14 (7) , 802
Corrigendum to ‘Adherence of Heart Failure Patients To Exercise: Barriers and Possible Solutions. A Position Statement of the Study Group on Exercise Training in Heart Failure of the Heart Failure Association of the European Society of Cardiology’ [Eur J Heart Fail 2012;14:451–458]
- 1 July 2012
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 14 (7) , 802
Corrigendum to ‘Adherence of Heart Failure Patients To Exercise: Barriers and Possible Solutions. A Position Statement of the Study Group on Exercise Training in Heart Failure of the Heart Failure Association of the European Society of Cardiology’ [Eur J Heart Fail 2012;14:451–458]